Citi Remains a Hold on CSL (CMXHF)

In a report released today, Laura Sutcliffe from Citi maintained a Hold rating on CSL, with a price target of A$110.00.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Sutcliffe is a 3-star analyst with an average return of 1.7% and a 51.16% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh.

In addition to Citi, CSL also received a Hold from Macquarie’s Christine Trinh in a report issued on June 30. However, on July 1, UBS maintained a Buy rating on CSL (Other OTC: CMXHF).

Citi analyst Laura Sutcliffe maintained a Hold rating on CSL (CMXHF) with an A$110 price target. This follows a June 30 Hold from Macquarie, while UBS issued a Buy rating on July 1. The report also notes TipRanks launched the RANK ETF tracking its US Momentum Analysts Index.

In a report released today, Laura Sutcliffe from Citi maintained a Hold rating on CSL, with a price target of A$110.00.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

In addition to Citi, CSL also received a Hold from Macquarie’s Christine Trinh in a report issued on June 30. However, on July 1, UBS maintained a Buy rating on CSL (Other OTC: CMXHF).